Is GE Healthcare Technologies, Inc. overvalued or undervalued?

As of 7 November 2025, the valuation grade for GE Healthcare Technologies, Inc. has moved from attractive to very attractive. The company appears to be undervalued, supported by a P/E ratio of 14, a PEG ratio of 0.39, and an EV to EBITDA ratio of 11.16, all of which suggest favorable valuation metrics compared to its peers. In comparison, Edwards Lifesciences Corp. has a significantly higher P/E ratio of 31.17, indicating it is considered expensive, while Agilent Technologies, Inc. has a fair valuation with a P/E of 27.42.
Despite a challenging year with a stock return of -14.5%, which underperformed the S&P 500's return of 12.65% over the same period, the company's strong ROCE of 18.89% and ROE of 25.79% highlight its operational efficiency and profitability. Overall, these factors suggest that GE Healthcare Technologies, Inc. is positioned as an attractive investment opportunity in the current market.